Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"AiCuris","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$220.0 million","upfrontCash":"$220.0 million","newsHeadline":"Royalty Pharma Acquires Partial Royalty Interest On Prevymis\u2122 (Letermovir) From Aicuris Anti-Infective Cures Gmbh","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AiCuris"},{"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"U.S. Food and Drug Administration Approves Lampit\u00ae (nifurtimox) for the Treatment of Chagas Disease in Children","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals Receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Peptide","graph2":"MYR Pharmaceuticals"},{"company":"MYR Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MYR Pharmaceuticals launches HEPCLUDEX\u00ae in Germany, France and Austria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Peptide","graph2":"MYR Pharmaceuticals"},{"company":"MYR Pharmaceuticals","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"$1,762.0 million","upfrontCash":"$1,400.0 million","newsHeadline":"Gilead Sciences to Acquire MYR GmbH","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Peptide","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Peptide","graph2":"MYR Pharmaceuticals"},{"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Vaccine","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"company":"BioNTech","sponsor":"U.S. Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Vaccine","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Vaccine","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"BioNTech"},{"company":"Evonik Industries","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evonik Strengthens Strategic Partnership with Biontech on Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Vaccine","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Evonik Industries"}]

Evonik Industries

Contact Supplier

Our CMO solutions- we specialize where you need us most!

Contact Supplier

Contact Supplier

Digital Content

Evonik Strengthens Strategic Partnership with Biontech on Covid-19 Vaccine

Details:

Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the partnership between Evonik and the Comirnaty, vaccine manufacturer BioNTech.

Lead Product(s): Tozinameran

Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty

Highest Development Status: Approved Product Type: Vaccine

Partner/Sponsor/Collaborator: BioNTech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership February 11, 2021

Evonik company banner

Beauty Accelerate 2022

Attending

envelop Contact Supplier

BioNTech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older

Details:

A first booster dose of the vaccine may be administered at least 5 months after completion of a primary series of the Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY® (COVID-19 Vaccine, mRNA) to individuals 12 years of age and older.

Lead Product(s): Tozinameran

Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty

Highest Development Status: Approved Product Type: Vaccine

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2022

ASK
US

Upload
your Pipeline Activity

BioNTech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries

Details:

The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series.

Lead Product(s): mRNA-based Covid 19 Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Comirnaty

Highest Development Status: Approved Product Type: Vaccine

Partner/Sponsor/Collaborator: U.S. Government

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration September 22, 2021

ASK
US

Upload
your Pipeline Activity

BioNTech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

BioNTech and Fosun Pharma to Supply China with mRNA-based COVID-19 Vaccine

Details:

BioNTech and Shanghai Fosun Pharmaceutical today announced an agreement to supply Mainland China with 100 million doses initially of their BNT162 mRNA-based vaccine candidate against COVID-19 in 2021, subject to regulatory approval.

Lead Product(s): BNT162

Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

Highest Development Status: Approved Product Type: Vaccine

Partner/Sponsor/Collaborator: Fosun Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 16, 2020

ASK
US

Upload
your Pipeline Activity

MYR Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Gilead Sciences to Acquire MYR GmbH

Details:

The acquisition will provide Gilead with Hepcludex™ (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020.

Lead Product(s): Bulevirtide Acetate

Therapeutic Area: Infections and Infectious Diseases Product Name: Hepcludex

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $1,762.0 million Upfront Cash: $1,400.0 million

Deal Type: Acquisition December 10, 2020

ASK
US

Upload
your Pipeline Activity

MYR Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MYR Pharmaceuticals launches HEPCLUDEX® in Germany, France and Austria

Details:

On July 31st HEPCLUDEX® was granted Conditional Marketing Authorization (CMA) by the European Commission as the first approved treatment in Europe for adult patients with chronic hepatitis delta virus (HDV) infection and compensated liver disease.

Lead Product(s): Bulevirtide Acetate

Therapeutic Area: Infections and Infectious Diseases Product Name: Hepcludex

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 17, 2020

ASK
US

Upload
your Pipeline Activity

Bayer AG

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children

Details:

U.S FDA has approved Lampit® (nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi (T. cruzi).

Lead Product(s): Nifurtimox

Therapeutic Area: Infections and Infectious Diseases Product Name: Lampit

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 07, 2020

ASK
US

Upload
your Pipeline Activity

MYR Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MYR Pharmaceuticals Receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX®

Details:

HEPCLUDEX® has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in Europe.

Lead Product(s): Bulevirtide

Therapeutic Area: Infections and Infectious Diseases Product Name: Hepcludex

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 04, 2020

ASK
US

Upload
your Pipeline Activity

AiCuris

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Royalty Pharma Acquires Partial Royalty Interest On Prevymis™ (Letermovir) From Aicuris Anti-Infective Cures Gmbh

Details:

Prevymis™ (letermovir) was approved by the US FDA in 2017 and by the EMA and Japan’s PMDA in 2018 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at high risk for CMV reactivation.

Lead Product(s): Letermovir

Therapeutic Area: Infections and Infectious Diseases Product Name: Prevymis

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Royalty Pharma

Deal Size: $220.0 million Upfront Cash: $220.0 million

Deal Type: Acquisition June 09, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY